Hemophilia Clinical Trial Pipeline Analysis: 20+ Key Companies Advancing the Future of Hemophilia Therapeutics | DelveInsight

DelveInsight's Hemophilia Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Hemophilia therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Hemophilia pipeline domain.

Key takeaways from the Hemophilia Clinical Trial Landscape Report
• DelveInsight's Hemophilia pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Hemophilia treatment.
• Key Hemophilia companies such as Roche, Regeneron Pharmaceuticals, Intellia Therapeutics, Suzhou Alphamab, Metagenomi Therapeutics, Equilibra Bioscience, Be Biopharma, and others.
• Promising Hemophilia pipeline therapies in various stages of development include NXT007, KN057, REGV131-LNP1265, MGX-001, SR604, and others.

Request a sample and discover the recent advances in Hemophilia treatment drugs at: https://www.delveinsight.com/sample-request/hemophilia-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Hemophilia?
Hemophilia is the most common severe hereditary hemorrhagic disorder. Both hemophilia A and B result from factor VIII and factor IX protein deficiency or dysfunction, respectively, and are characterized by prolonged and excessive bleeding after minor trauma or sometimes even spontaneously. Hemophilia is usually an inherited condition and is caused by the deficiency of clotting factors in the blood. The encoding genes for factors VIII and factor IX are present in the long arm of chromosome X.

Hemophilia is a genetic bleeding disorder caused by a deficiency of clotting factors, which leads to impaired blood clotting and prolonged bleeding. Individuals with hemophilia may experience spontaneous or excessive bleeding after injuries, medical procedures, or minor trauma. Repeated bleeding episodes, particularly in joints and muscles, can result in pain, swelling, and long-term complications if untreated.

The management of hemophilia mainly focuses on preventing bleeding episodes and controlling acute bleeding when it occurs. The treatments include clotting factor replacement therapy, desmopressin, antifibrinolytic drugs, and gene therapy.

Emerging Hemophilia Drug Profiles

NXT007: Hoffmann-La Roche
NXT007 is a next-generation investigational bispecific antibody being investigated as a prophylactic treatment option for people with hemophilia. NXT007 was engineered by Chugai, a member of the Roche Group, with the aim of optimizing factor VIII-mimetic activity and half-life to further enhance potency, efficacy, dosing, and administration convenience. This drug brings together factor IXa and factor X proteins required to activate the natural coagulation cascade. Currently, the drug is in the Phase III stage of its development for the treatment of Hemophilia A.

BE-101: Be Biopharma
BE-101 is a gene therapy candidate being developed by Be Biopharma for Hemophilia treatment. The therapy is currently in Phase I/II clinical development and is administered intravenously.

Learn more about the novel and emerging Hemophilia pipeline therapies at: https://www.delveinsight.com/sample-request/hemophilia-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Recent Developments in the Hemophilia Clinical Trial Landscape
• In February 2026, Chugai Pharmaceutical announced new data from Part C of the Phase I/II NXTAGE study of NXT007, evaluating patients who switched directly from emicizumab without a washout period.
• In June 2025, Roche presented positive Phase I/II NXTAGE study data for NXT007 at the ISTH Congress, showing that the bispecific antibody achieved zero treated bleeds in the highest dose cohorts and demonstrated a favorable safety profile.
• In November 2025, Metagenomi Inc. announced new preclinical data for its hemophilia A gene-editing therapy MGX-001, demonstrating curative levels of factor VIII activity in non-human primates. The company plans to submit IND/CTA applications in 2026 to initiate first-in-human clinical trials.
• In September 2025, Novo Nordisk A/S submitted a Biologics License Application to the US FDA seeking approval for Mim8 (denecimig), an investigational subcutaneous prophylactic therapy for Hemophilia A with or without inhibitors.
• In June 2025, Roche continued to advance its hemophilia gene therapy portfolio following the acquisition of Spark Therapeutics, strengthening its capabilities in gene therapy development and expanding its presence in the bleeding disorders therapeutic area.

Scope of the Hemophilia Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination
• Therapeutic Assessment By Clinical Stages: Preclinical, Phase I, Phase I/II, Phase III
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous
• Therapeutics Assessment By Molecule Type: Bispecific Monoclonal Antibody, Monoclonal Antibody, Gene Therapy, Blood Coagulation Factor Modulator
• Key Hemophilia Companies: Roche, Regeneron Pharmaceuticals, Intellia Therapeutics, Suzhou Alphamab, Metagenomi Therapeutics, and others
• Key Hemophilia Pipeline Therapies: NXT007, KN057, REGV131-LNP1265, MGX-001, SR604, and others

Dive deep into rich insights for new drugs for Hemophilia treatment, visit at: https://www.delveinsight.com/sample-request/hemophilia-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
1. Hemophilia Pipeline Report Introduction
2. Hemophilia Pipeline Report Executive Summary
3. Hemophilia Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Hemophilia Pipeline Therapeutics
6. Hemophilia Pipeline: Late Stage Products (Phase III)
7. Hemophilia Pipeline: Mid Stage Products (Phase II)
8. Hemophilia Pipeline: Early Stage Products (Phase I/II)
9. Hemophilia Pipeline Therapeutics Assessment
10. Inactive Products in the Hemophilia Pipeline
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products in the Hemophilia Pipeline
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

For further information on the Hemophilia pipeline therapeutics, reach out at: https://www.delveinsight.com/sample-request/hemophilia-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.